MedTrace Logo

Adjuvant Treatment of Concurrent RT and CAPOX or Capecitabine Alone for Stage II and III Rectal Cancer

NCT00714077 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 570

Last updated 2016-02-17

No results posted yet for this study

Summary

The purpose of this study is:

* To compare the long-term of survival and local/regional control between the two postoperative concurrent chemoradiotherapy regimens: capecitabine vs. oxaliplatin and capecitabine,for stage II and III rectal cancer
* To compare the toxicity profile between the two different concurrent chemoradiotherapy regimens.

Conditions

  • Rectal Neoplasms

Sponsors & Collaborators

  • Zhejiang Cancer Hospital

    collaborator OTHER

  • Cancer Hospital of Guizhou Province

    collaborator OTHER

  • Shandong Cancer Hospital and Institute

    collaborator OTHER

  • Hebei Medical University Fourth Hospital

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • General Hospital of Chinese Armed Police Forces

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Yexiong Li, M.D. · CAMS

  • Jing Jin, M.D.;Ph.D · CAMS

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2018-01-31
Completion
2018-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714077 on ClinicalTrials.gov